WGS

GeneDx Holdings Corp. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-02-23

Figures on this page computed 2026-11-08 12:48 UTC

Last close

69.34USD

Market data, 2026-11-04

Except where said otherwise: 10-K for 2025, filed 2026-02-23

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001818331-26-000015
Reported in
USD
- computed
- 10-K for 2025, filed 2026-02-23
The filing itself
-4.1%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001818331-26-000015
Reported in
USD
- 10-K for 2025, filed 2026-02-23
- 10-K for 2025, filed 2026-02-23
- 10-K for 2025, filed 2026-02-23
- 10-Q for 2025, filed 2026-08-03
- 10-K for 2025, filed 2026-02-23
- 10-Q for 2025, filed 2026-08-03
The filing itself
-4.9%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001818331-26-000015
Reported in
USD
- 10-K for 2025, filed 2026-02-23
- 10-K for 2025, filed 2026-02-23
The filing itself
3.3%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001818331-26-000015
Reported in
USD
- 10-K for 2025, filed 2026-02-23
- 10-K for 2025, filed 2026-02-23
The filing itself
0.37Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001818331-26-000015
Reported in
USD
- 10-K for 2025, filed 2026-02-23
- 10-Q for 2025, filed 2026-08-03
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Price is the furthest below its sector's middle: 0.21 against 0.38 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

1.70x

0.11x

-0.11x

1.41x

0.59x

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Filed2025

Market data2026-11-04

Each against its own average

5 of 5 read

Except where said otherwise: 10-K for 2025, filed 2026-02-23

Sales1.70x
Its own average over 7 years, 251.1M.
Profit0.11x
Its own average over 7 years, -187.8M.
Free cash flow-0.11x
Its own average over 7 years, -125.6M.
Debt1.41x
Its own average over 6 years, 80.2M.
Price0.59x
Its own average over 7 years, 117. Market data, 2026-11-04

Free cash flow is furthest from its own average, at -0.11 times.

Sales is 1.70 times its own 7-year average; Profit is 0.11 times its own 7-year average; Free cash flow is -0.11 times its own 7-year average; Debt is 1.41 times its own 6-year average; Price is 0.59 times its own 7-year average.

Every figure in this lens

Except where said otherwise: 10-K for 2025, filed 2026-02-23

Sales against its own 7-year average1.70
Source
filed
Statement
income
Fiscal year
2025
Accession
0001818331-26-000015
Reported in
USD
The filing itself
Profit against its own 7-year average0.11
Source
filed
Statement
income
Fiscal year
2025
Accession
0001818331-26-000015
Reported in
USD
The filing itself
Free cash flow against its own 7-year average-0.11
Source
filed
Statement
income
Fiscal year
2025
Accession
0001818331-26-000015
Reported in
USD
The filing itself
Debt against its own 6-year average1.41
Source
filed
Statement
income
Fiscal year
2025
Accession
0001818331-26-000015
Reported in
USD
The filing itself
Price against its own 7-year average0.59Market data, 2026-11-04
Source
market
Taken on
2026-11-04
Reported in
USD